Abstract | When cells are stimulated with pro-inflammatory cytokines, most of their constitutively expressed proteasomes are replaced with immunoproteasomes, which increase the production of peptides for presentation on MHC class I molecules. In addition, cortical thymic epithelial cells selectively express a type of proteasome known as the thymoproteasome that is required for the positive selection of thymocytes. Here, we discuss how these specialized types of proteasome shape the T cell receptor repertoire of cytotoxic T lymphocytes and propose that immunoproteasomes have functions, in addition to antigen processing, that influence cytokine production and T cell differentiation, survival and function. We also discuss how inhibitors of immunoproteasomes can suppress undesired T cell responses in autoimmune diseases.
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. In both direct and crosspresentation pathways, the proteasome is the protease that deter mines the carboxyterminal anchor residues of MHC class Ibinding peptides. The protea some produces peptides of 8-9 amino acids that can bind directly to the peptidebinding cleft of MHC class I molecules and it also produces aminoterminally extended pre cursor peptides that are processed further by aminopeptidases in the cytoplasm or endoplasmic reticulum 2 (FIG. 1) .
The proteasome is an evolutionarily ancient enzyme and is present in a simplified form in archaebacteria 3 . Because of the evolu tionary conservation of the proteasome, it has been proposed that the entire MHC class I restricted antigen presentation pathway has evolved to accommodate the peptides that the proteasome generates 4 . The proteasome con sists of a central proteolytic unit, known as the 20S proteasome, and the 19S regulator, which together make up a 26S structure 5 . Moreover, the interferonγ (IFNγ)inducible heterohep tameric regulator proteasome activator 28 (PA28) which is composed of PA28α (also known as PSME1) and PA28β (also known as PSME2) subunits 6, 7 , can associate with the 26S proteasome to form the 'hybrid' proteasome 8 . Evidence from mutant cell lines 9 ,10 and mice 11 shows that PA28 influences antigen process ing by either affecting peptide cleavage 12, 13 or facilitating the release of peptide products from the proteasome complex 14 . The cylindrical 20S proteasome consists of four heteroheptameric rings: two outer rings composed of seven αtype structural sub units and two inner rings composed of seven βtype structural and proteolytic subunits. Most mammalian tissues express 'constitutive' proteasomes, in which the proteolytic activity is mediated by proteasome subunit β1 (also known as PSMB6, Y and δ), which cleaves after acidic residues (caspaselike activity), proteasome subunit β2 (also known as PSMB7, Z and MC14), which cleaves after basic residues (trypsinlike activity), and pro teasome subunit β5 (also known as PSMB5, X, MB1 and ε), which cleaves after hydrophobic residues (chymotrypsinlike activity) (FIG. 2) .
With the exception of β5, the proteolytic activities of the constitutive proteasome subunits do not fully match the require ments for the generation of MHC class I ligands. Human MHC class I molecules accommodate peptides with hydrophobic residues (products of β5mediated cleavage) and occasionally basic residues (products of β2mediated cleavage) at their Ctermini, whereas mouse MHC class I molecules only accommodate peptides with hydro phobic Cterminal residues. Peptides with acidic Cterminal residues (products of β1mediated cleavage) have an inappropriate Cterminus and cannot function as MHC class I ligands in mice or humans 15 .
In the early 1990s, two additional βtype proteasome subunits, designated proteasome subunit β1i (also known as PSMB9 and LMP2) and proteasome subunit β5i (also known as PSMB8 and LMP7) were identi fied [16] [17] [18] [19] . These subunits, which are highly homologous to β1 and β5, respectively, are encoded by genes in the MHC class II region adjacent to the genes encoding transporter associated with antigen processing 1 (TAP1) and TAP2, and the expression of β1i and of β5i are strongly and synergistically induced by the pro inflammatory cytokines IFNγ and tumour necrosis factor (TNF) 20 . Subsequently, another cytokineinducible proteasome subunit with homology to β2, proteasome subunit β2i (also known as PSMB10, LMP10 and MECL1), was found outside the MHC region [21] [22] [23] . After stimulation with IFNγ and/or TNF, expression of these three inducible 'immunosubunits' is strongly upregulated and the neosynthesis of 20S proteasomes is switched almost exclusively to the generation of a type of proteasome known as the immunoproteasome 24, 25 . Indeed, by eight days after infection of mice with a virus, bacterium or fungus, constitu tive proteasomes in the liver and other tissues are almost completely replaced by immuno proteasomes 26, 27 . However, despite nearly two decades of research, the specific reasons for this exchange of proteasome subunits are not completely understood.
The pool of MHC class I ligands that is generated by the immunoproteasome is both distinct from and more efficient at CTL activation than the ligand pool gener ated by the constitutive proteasome 28, 29 . This is a result, in part, of the replacement of β1 with β1i, which leads to the elimination of the caspaselike activity of β1 and enhance ment of the chymotrypsinlike activity of β1i and therefore to the generation of peptides with hydrophobic Cterminal residues 25, [30] [31] [32] [33] [34] . Mice lacking one or more of the inducible immunosubunits have been generated and infected with commonly used laboratory strains of viruses, bacteria and fungi 35, 36 . These studies have indicated roles for the immunoproteasome in shaping the CTL repertoire and in pathogen clearance that have, until recently (see later), been ascribed to alterations in the MHC class I ligands that are generated.
In cortical thymic epithelial cells (cTECs), which are involved in the positive selection of T cells in the thymus, a third type of specialized proteasome (the thymo proteasome) has been discovered that, in addition to the immunosubunits β1i and β2i, also contains the cTECspecific proteasome subunit β5t (also known as PSMB11), which seems to be essential for the positive selection of CD8 + T cells 37 . Immunoproteasomes and thymoproteas omes are thought to function in shaping CTL responses at the level of antigen presentation. In this article, we review these insights into the biology of immuneassociated proteas omes and propose, based on recent data, that immunoproteasomes also have a role in the control of cytokine production and T cell differentiation. The therapeutic implications of these immunoproteasome functions that are independent of antigen processing in immune responses are also discussed.
immunoproteasome-deficient mice
The discovery of the genes encoding β1i and β5i in the MHC region led researchers to assume that they would have important functions in the immune response, but initial functional and phenotypic analyses of knock out mice were disappointing. β1ideficient mice generated normal CTL responses to Sendai virus and to ovalbumin and cleared lymphocytic choriomeningitis virus (LCMv) infection; CTL responses to the LCMv epitopes GP33, GP276 and NP396 were unaltered in these mice 38 . The CTL response to influenza virus infection in β1ideficient mice was skewed towards the subdominant epitopes of the virus (PB1F2.61 and NS2.114) and away from two immunodominant epitopes (NP366 and PA224) 39 . Despite the initial report that splenocytes from β5i deficient mice generate a decreased number of CTLs specific for the male minor antigen HY 36 , we observed normal responses to all dominant LCMv epitopes and normal kinet ics of viral clearance in β5ideficient mice 38 . However, after challenge with recombinant vaccinia virus or a DNA vaccine encod ing the LCMv glycoprotein, an increased response to the LCMv epitope GP276 was detected in β5ideficient mice, which indi cates that the immunoproteasome down regulates the presentation of this epitope in wildtype mice 38, 40 . A role for β5i in the clearance of patho gens was first shown in knockout mice after infection with Listeria monocytogenes 41 . Similar to LCMv infection, infection with L. monocytogenes results in the upregulation of immunoproteasome expression and the replacement of constitutive proteasomes in the liver 26 . Although L. monocytogenes specific CTLs were generated at a normal frequency in β5ideficient mice, the clearance of bacteria from the liver was not apparent by day 10, by which time bacterial burden in the spleen of wildtype mice had decreased 41 . This result underscores the necessity to induce immunoproteasomes at sites of infection for pathogen clearance, most prob ably because the effective CTL response is focused on immunoproteasomedependent pathogen epitopes.
An even more prominent phenotype was seen when β5ideficient mice were infected with the protozoan parasite Toxoplasma gondii 42 . In contrast to wildtype mice, β5i deficient mice succumbed to infection and Proteins that are synthesized in the cell (direct presentation) or are released from endosomes (cross-presentation) are polyubiquit y lated in the cytoplasm and degraded by hybrid proteasomes consisting of the 20s proteasome core, the 19s regulator and PA28. The peptides that are produced are either of the ideal length for binding to MHC class I molecules (8-9 amino acids) or are amino-terminally extended precursors that can be further cleaved by aminopeptidases in the cytoplasm (such as leucine aminopeptidase, puromycin-sensitive aminopeptidase, bleomycin hydrolase and tripeptidyl peptidase II). Chaperones (such as heat shock protein 70 (HsP70), HsP90α and TriC) can stabilize the peptides in the cytoplasm to prevent their rapid degradation (for example by tripeptidyl peptidase II or thimet oligopeptidase). Transporter associated with antigen processing 1 (TAP1) and TAP2, which are attached to nascent MHC class I chains through tapasin, transport the peptides into the endoplasmic reticulum (er), where they can be further trimmed at the N-terminus by er aminopeptidase 1 (erAP1) and erAP2. The oxidoreductase erp57 ensures the maintenance of disulphide bridges in the MHC class I loading complex. Note that the carboxyl terminus of a peptide ligand for MHC class I molecules is mainly determined by protea somal cleavage. The binding of peptides with high affinity to the MHC class I heavy chain-β 2 -microglobulin (β 2 m) complex induces a final folding and release of the MHC class I molecule from the er lumenal chaperone calreticulin to allow exit from the er and migration through the Golgi to the plasma membrane. TCr, T cell receptor.
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this correlated with decreased production of IFNγ by parasitespecific CD8 + T cells. Immunodominant epitopes of the T. gondii specific CTL response have not been identi fied and it remains to be shown whether the decreased generation of activated CTLs in β5ideficient mice is a result of the lack of presentation of β5idependent T. gondii epitopes or whether additional functions of β5i might explain this phenotype. Taken together, these results show that the require ment for immunoproteasomes for pathogen elimination varies markedly between infec tion models and further testing of immuno proteasomedeficient mice is required to fully appreciate the contribution of indi vidual proteasome subunits to the immune response to infectious agents.
Stimulation of cells with IFNγ or TNF typically leads to a tenfold upregulation of the cell surface expression of MHC class I molecules 43 . Through increased ligand production, switching to the generation of immunoproteasomes provides the larger pool of peptides that is required to allow the increased number of MHC class I molecules to finalize their folding in the endoplasmic reticulum and to migrate to the cell surface. Evidence of a role for β5i in contributing to the increased cell surface expression of MHC class I molecules has been obtained in β5i deficient mice, which have a 50% decrease in cell surface expression of MHC class I mol ecules by lymphocytes and monocytes com pared with wildtype mice 36 . Remarkably, no decrease in the cell surface expression of MHC class I molecules has been observed in β1i or β2ideficient mice 35, 44 . The nor mal level of MHC class I expression on the cell surface of β1i but not β5ideficient splenocytes (as determined by flow cytom etry) is surprising as β1i contributes to the generation of MHC class Ibinding peptides by replacing the caspaselike activity of β1 with the chymotrypsinlike activity of β1i. These data indicate that β5i produces higher affinity MHC class I ligands than does β5, which was not predicted from structural models of the two subunits 33 . Decreased cell surface MHC class I expression might be predicted to affect the number of CD8 + T cells in β5ideficient mice. However, a surprising finding was a 20-30% decrease in the number of CD8 + T cells com pared with CD4 + T cells in the thymus, blood and spleen of β1i or β2ideficient mice, but not β5ideficient mice 35, 45 . As these findings did not correlate with MHC class I expression levels, it is possible that they were a result of intrinsic T cell effects. Indeed, this has been elegantly shown using bone marrow chimae ras in which wildtype recipient mice received equal numbers of cells from wildtype and from β5i and β2i doubledeficient donors. The decreased ratio of CD8 + to CD4 + T cells was maintained in the thymus and periphery for β5i and β2i doubledeficient donor cells in wildtype recipient mice, whereas wildtype donor cells had normal numbers of both cell subsets 46 . As the two donor populations were selected by the same wildtype thymus and expanded in the same wildtype periphery, this phenomenon cannot be attributed to a difference in antigen presentation. Rather, it seems that CD8 + T cells deficient in β5i and β2i expand less readily than wildtype CD8 + T cells. This finding clearly hints at a previ ously overlooked function of immunoprotea some subunits in the proliferative expansion of CD8 + T cells.
TCR repertoire formation
The cells that are responsible for negative selection and TCR repertoire formation in the thymus -thymic dendritic cells and medullary thymic epithelial cells (mTECs) -constitutively express high levels of immuno proteasomes (FIG. 3) . By contrast, cTECs, which support the positive selection of T cells, also express immunoproteasome sub units but only after systemic infection or the administration of IFNγ
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. Therefore, it is not surprising that immunoproteasomes shape the repertoire of CD8 + T cells in the thymus. It has been shown that the lack of NP366 specific CTLs in β1ideficient mice infected with influenza virus is not owing to the ina bility of β1ideficient splenocytes to present the epitope for the activation of CTLs, as was previously reported 35 , but instead is owing to the lack of NP366specific precursor T cells in the periphery of knockout mice 39 . In addi tion, β2ideficient mice infected with LCMv mounted a normal CTL response to most LCMv epitopes but the response to GP276 was markedly decreased 44 . Again, this defect was not caused by the inability of β2ideficient antigenpresenting cells (APCs) to process and present the GP276 epitope to CTLs but by a decrease in the number of GP276specific precursor T cells in the knockout mice.
Differences in T cell selection in the thy mus can be best observed in TCRtransgenic mice. CD8 + T cells from oT1 mice, which express a TCR that is specific for the oval bumin epitope SIINFEKL presented by the MHC class I molecule H-2K b , did not undergo positive selection in the absence of β5i (ReF. 48) . In vitro processing of the Cpα1 92-99 self peptide derived from the Factin capping protein Cpα1, which contributes to the posi tive selection of oT1 cells, can be mediated by immunoproteasomes but not by constitu tive proteasomes. Furthermore, repeated injection of β5ideficient oT1 mice with syn thetic Cpα1 92-99 peptide rescued the positive selection of oT1 cells, which emphasizes the role of β5i in this process.
Although this finding strongly supports the involvement of immunoproteasomes (and β5i in particular) in positive selection, it is dif ficult to reconcile the result with the failure to detect β5i mRNA and protein in cTECs from noninfected mice 47 and with the recent find ing that β5i is replaced by the cTECspecific subunit β5t in these cells (see below).
Thymoproteasomes in T cell selection
The interest in the role of immunetype proteasomes in TCR repertoire selection has recently been boosted by the dis covery of a seventh active subunit of the The proteolytic subunits of the constitutive proteasome are β1 (also known as PsMB6, Y and δ), β2 (also known as PsMB7, Z and MC14) and β5 (also known as PsMB5, X, MB1 and ε). The proteolytic immunoproteasome subunits are β1i (also known as PsMB9 and LMP2), β2i (also known as PsMB10, LMP10 and MeCL1) and β5i (also known as PsMB8 and LMP7). The proteolytic thymoproteasome subunits are β1i, β2i and β5t (also known as PsMB11). Compared with the constitutive proteasome, the immunoproteasome has a strongly decreased caspase-like activity and an increased chymotrypsin-like activity, whereas the thymoproteasome has a decreased chymotrypsin-like activity. mammalian proteasome known as β5t, which is expressed exclusively by cTECs in mice 37 and humans 49 . β5t from mouse thymus lysates coimmunoprecipitates with β1i and β2i, but not with β1 or β2 proteasome subunits 37 . This β1i-β2i-β5tcontaining proteasome has been designated the thymo proteasome to distinguish it from the β1i-β2i-β5icontaining immunoproteasome (FIG. 2) . In contrast to the classical immuno subunits (β1i and β2i), expression of β5t is not induced by IFNγ. Ly51 + cTECs were shown to express low levels of the protea some subunits β1, β2, β5 and β5i, whereas β1i, β2i and β5t were highly expressed 37 . This result is in conflict with an earlier report that showed that mouse cTECs express the con stitutive proteasome subunits β1, β2 and β5 and only express the immunosubunits β1i, β2i and β5i after infection or IFNγ stimula tion in vivo 47 . These disparate results could be explained by differences in infection status and cytokine levels in the mice or by the presence of other cell types in the cTEC prep arations. Further investigation of the protea some subunits that are expressed by cTECs from naive and infected mice is warranted to determine if inducing the expression of β5i can replace β5t in proteasome assembly in cTECs as it does for β5 in other tissues.
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Why does a highly specialized cell type that has evolved to mediate positive selection in the thymus require a unique β5type proteasome subunit? Examination of the S1 pocket of β5t, which accommo dates the amino acid directly before the polypeptide cleavage site, shows that it is lined with hydrophilic residues rather than the hydrophobic residues that are present in β5 and β5i (ReF. 37) . This change in the S1 pocket decreases the chymotrypsin like activity (cleavage after hydrophobic residues) of β5t by 60-70%, and probably affects the pool of available ligands for MHC class I molecules that are generated. Peptides with hydrophilic Ctermini (such as those produced by β5t) are predicted to be poor ligands for MHC class I molecules, and although there are normal numbers of doublenegative, doublepositive and CD4 singlepositive (SP) thymocytes in β5tdeficient mice, the number of CD8 SP thymocytes and peripheral CD8 + T cells is decreased by 75% in these mice 37 (FIG. 3) .
The expression profile, biochemical prop erties and effect on thymic selection of β5t are all consistent with a role for this proteasome subunit in the positive selection of CD8 + T cells, but one finding has remained puz zling: lowaffinity MHC class I ligands should negatively affect the cell surface expression of MHC class I molecules but this correla tion was not found for β5tdeficient cTECs 50 . Why do β5tdeficient cTECs have such a marked deficit in positive selection when the level of MHC class I cellsurface expression is not changed? It was speculated that the β5tdependent peptide repertoire of cTECs is better suited for positive selection and that the peptide repertoire on which positive selection occurs should be different from the peptide repertoire of negatively selecting APCs 50 . The requirement of a special peptide population for positive selection is not fully consistent with the demonstration that a single peptide can positively select a large and diverse TCR repertoire 51 . one possible explanation could be that cTECs have mechanisms to better sta bilize MHC class I molecules complexed with lowaffinity peptide ligands. Alternatively, the β5tgenerated peptide ligands could achieve a higher affinity for MHC class I molecules by the use of MHC anchor positions other than the Cterminal position; an experimen tal determination of the dissociation rates of MHC class I ligands in β5texpressing cells should clarify this issue. Together, these results show that it is probable that the production of lowaffinity peptide ligands for MHC class I molecules underlies the phenotype of β5tdeficient mice, but there is some room for alternative mechanisms.
immunoproteasomes in T cell survival
In addition to its role in shaping the anti genic peptide repertoire presented by MHC class I molecules, the immunoproteasome might have other roles in regulating immune responses. As mentioned earlier, after adop tive transfer into wildtype mice, T cells from β1ideficient mice fail to proliferate in response to influenza virus infection, despite the robust proliferation of host T cells 39 . It has been argued that this could be attributed to the rejection of β1ideficient donor T cells by the wildtype host because the donor cells present a different peptide repertoire on their MHC class I molecules 52 .
An argument against such a rejection phe nomenon is provided by the finding that skin from β5ideficient mice transplanted onto wildtype mice was not rejected by the host 53 . Strikingly, when β2ideficient T cells were transferred into LCMvinfected wildtype mice, they also did not survive 44 . As the cell surface expression level of MHC class I molecules is not altered in β1i or β2ideficient mice and as no major change in the specificity of proteasomal cleavage could be observed in β2ideficient mice 44 , we think that the disappearance of β1i or ) thymocyte stage and is mediated by cortical thymic epithelial cells (cTeCs). These highly specialized antigen-presenting cells express a unique type of proteasome, known as the thymoproteasome, which contains the active site subunits β1i, β2i and the cTeC-specific subunit β5t. Low-affinity interactions with the T cell receptor for the positive selection of CD8 singlepositive (sP) thymocytes probably rely on a spectrum of weak peptide-MHC class I ligands with hydrophilic carboxy-termini that are generated by the thymoproteasome. Medullary thymic epithelial cells (mTeCs) and dendritic cells (DCs) mediate the negative selection of self-reactive thymocytes at the boundary of the cortex and medulla. Both cell types express high levels of immunoproteasomes containing the active site subunits β1i, β2i and β5i, as well as constitutive proteasomes containing β1, β2 and β5. The negative selection of CD8 sP thymocytes relies on high-affinity peptide-MHC class I ligands and should involve peptides generated from self antigens by both types of proteasome that are encountered in the periphery (the constitutive proteasome and the immunoproteasome).
β2ideficient T cells after transfer into virus infected wildtype mice is not the result of rejection but instead reflects the requirement of these immunoproteasome subunits for the survival of T cells in a proinflammatory environment. Based on this notion, we pos tulate that the immunoproteasome could be a suitable drug target for the suppression of overactive T cell responses such as are found in many autoimmune diseases.
β5i inhibition blocks autoimmunity The data generated from knockout mice highlight two important aspects of the biol ogy of the immunoproteasome: first, the inducible subunits of the immunoprotea some have nonredundant immunoregula tory functions; and second, compensatory mechanisms and altered proteasome struc ture in subunitdeficient cells might compli cate the search for specific pathways that are regulated by the immunoproteasome. A need for specific inhibitors of immunoproteasome subunits is evident. Small molecule inhibi tors of the proteasome have been used in research since 1994 (ReF. 54) and the dipeptide boronate proteasome inhibitor bortezomib (velcade; Millennium Pharmaceuticals) is used for the treatment of malignant diseases, such as multiple myeloma 55 . However, these inhibitors do not selectively target immuno proteasome subunits and, so far, their clinical use has been restricted to the treatment of cancer owing to drug side effects.
Recently, a cellpermeable ketoepoxide based immunoproteasome inhibitor, desig nated PR957, which selectively inhibits β5i in both human and mouse cells at concentra tions that do not target other proteasome subunits, has been developed 56 . The selectivity of PR957 was verified by its ability to down regulate MHC class I cell surface expression by 50% in wildtype but not β5ideficient mice and to suppress the presentation of β5i dependent peptide epitopes, such as uty [246] [247] [248] [249] [250] [251] [252] [253] [254] (derived from the male minor antigen HY) and LCMv GP33, without affecting the presentation of β5iindependent epitopes.
As PR957 suppressed the presentation of the LCMv GP33 epitope in vivo, we investigated whether PR957 could prevent diabetes in RIP-GP mice, which express a fragment of the LCMv glycoprotein epitope in βislet cells under the control of the rat insulin promoter (RIP) and develop diabe tes after infection with LCMv 57 . Treatment with PR957 completely prevented the onset of disease after virus challenge in RIP-GP mice, highlighting the role of β5i in the production of the immunodominant LCMv GP33 epitope 56 , which could not be fully appreciated in experiments with β5i deficient mice most probably owing to the concomitant lack of β1i and β2i 38 . The role of β5i in immune responses is not restricted to T cells. We found that selectively targeting β5i in human peripheral blood mononuclear cells (PBMCs) blocked the production of several proinflammatory cytokines, including interleukin6 (IL6), IL23 and TNF 56 . The level of inhibition varied for each cytokine but was equivalent in PBMCs derived from healthy volunteers and from patients with active rheumatoid arthritis, which indicates that immunomodu lation through targeting β5i might be feasible in patients with rheumatoid arthritis. The suppression of IL6 and IL23 production is intriguing given that these cytokines have a crucial role in the development and/or main tenance of T helper 17 (T H 17) cells, which are involved in the pathogenesis of several autoimmune diseases, including rheuma toid arthritis, inflammatory bowel disease and psoriasis 58 . Interestingly, β2ideficient mice have been shown to be protected from dextran sulphate sodiuminduced colitis, which is a T cellindependent mouse model of inflammatory bowel disease 59 . PR957 suppressed the development of T H 1 and T H 17 cells in vitro from both mouse and human naive T cells but did not affect the differentiation of regulatory T cells and T H 2 cells 56 (E. Suzuki, C.j.K., M.B. and K. Kalim, unpublished observations).
We extended these in vitro data to show that PR957 could block disease progression in mouse models of rheumatoid arthritis. Inhibition of β5i suppressed disease symp toms in both collageninduced arthritis (CIA) and collagen antibodyinduced arthri tis (CAIA) and was more effective than the soluble TNF antagonist etanercept 56 . PR957 suppressed disease symptoms at doses of less than onetenth the maximum tolerated dose, a therapeutic window that is not achievable with nonselective inhibitors. The efficacy of PR957 in the T cellindependent CAIA model highlights the immunoregulatory role of β5i outside of antigen presentation that, consistent with in vitro data, involves multi ple immune effector cell types. Therapeutic activity of PR957 in mouse models of colitis, dermatitis and lupus has also been noted (T. Muchamuel, C.j.K., M.B. and M.G., unpublished observations).
Conclusions and perspectives
Despite the initial studies with immuno proteasomedeficient mice that indicated a mild phenotype, more recent studies involving pathogen infection models have shown that immunoproteasome sub units have distinct functions in pathogen elimination 41, 42 . Further studies with both knockout mice and selective inhibitors will enable a more complete understand ing of how the immunoproteasome and thymoproteasome shape the antigenic repertoire and regulate the CTL response to infectious agents. However, questions remain about the role of specific subunits in immune responses. It is unclear why β5i but not β1i or β2i deficiency decreases the cell surface expression of MHC class I molecules but the number of CD8 + T cells is decreased in β1i or β2ideficient mice, but not β5ideficient mice. What are the pathways that are regulated by the immuno proteasome that underlie its role in the proliferative expansion of T cells in a pro inflammatory environment? Are these pathways similar to the pathways that are regulated by β5i during cytokine production by T cells and monocytes?
The development of the specific β5i inhibitor PR957 has opened new and interesting avenues of research into immuno proteasome biology. Further work is required to fully understand the unique role of the immunoproteasome in the induc tion and maintenance of inflammation. The suppression of T H 1 and T H 17 cell differentia tion by PR957 indicates that the immuno proteasome is a possible target for therapeutic intervention in several autoimmune diseases. However, it is unclear how the immuno proteasome is mechanistically involved in these processes. We propose that the immuno proteasome selectively processes a factor that is required for regulating cytokine production. Clearly, more research, including the development of selective inhibitors of β1i and β2i, is required. Clinical investiga tion with PR957 in autoimmune disease will bring the immunoproteasome forward as a drug target and extend these interest ing preclinical findings. From subtle pheno types in genedeficient mice to a drug target in inflammatory diseases, the immunoproteasome is back in the limelight.
